Proven safety of a dedicated
bifurcation DES with an abluminal
biodegradable polymer
Proven safety of a dedicated
bifurcation DES with an abluminal
biodegradable polymer
Confirmed safety in DIVERGE
| 1. | 4 - year clinical outcomes of dedicated bifurcation Axxess™ stent in DIVERGE trial, document 11059-000 at Biosensors Intl |
| 2. | Verheye, S. et al., “9-Month Clinical, Angiographic, and Intravascular Ultrasound Results of a Prospective Evaluation of the Axxess Self-Expanding Biolimus A9-Eluting Stent in Coronary Bifurcation Lesions. The DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) Study”, J Am Coll Cardio 2009;53:1031–9 |
| 3. | Definite stent thrombosis dened by ARC (Cutlip et al. “Clinical End Points in Coronary Stent Trials: A Case for Standardized Denitions”). Circulation. 2007; 115(17): 2344-51. Differs from protocol definition |
CAUTION: The law restricts these devices to sale by or on the order of a physician. Prior to use, it is important to read the "Instructions for Use" supplied with these devices for indications, contraindications, suggested procedures, warnings, and precautions.
Biosensors’ interventional cardiology products, including BioMatrix Flex™, BioMatrix™, Axxess™, BioFreedom™, Gazelle™, Juno™, S-Stent™, Powerline™, Quadrature Link™ and MultiPleat™, are not available for sale in the United States and certain other countries. BioFreedom™ is an investigational device. All other trademarks are the property of their respective owners.
BioMatrix Flex, BioMatrix, Axxess, BioFreedom, Gazelle, Juno, S-Stent, Powerline, Quadrature Link and MultiPleat are trademarks or registered trademarks of Biosensors International Group, Ltd. in the United States and certain other countries. All cited trademarks are the property of their respective owners.
Watch the working principle of our Axxess™ self-expanding bifurcation DES



